New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacia limited company trading as pharmacia - disopyramide phosphate 193.2mg;  ;   - modified release tablet - 150 mg - active: disopyramide phosphate 193.2mg    

United States - English - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc - disopyramide phosphate (unii: n6bom1935w) (disopyramide - unii:gfo928u8mq) - disopyramide 100 mg - norpace and norpace cr are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. because of the proarrhythmic effects of norpace and norpace cr, their use with lesser arrhythmias is generally not recommended. treatment of patients with asymptomatic ventricular premature contractions should be avoided. initiation of norpace or norpace cr treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. norpace cr should not be used initially if rapid establishment of disopyramide plasma levels is desired. antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. norpace and norpace cr are contraindicated in the presence of cardiogenic shock, preexisting second-or third-degree av block (if no pacemaker is present), congenital q-t prolongation, or known hypersensitivity to the drug.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - nevirapine (unii: 99dk7fvk1h) (nevirapine - unii:99dk7fvk1h) - nevirapine 400 mg - viramune xr is indicated for use in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and in children 6 to less than 18 years of age [see clinical studies (14.1, 14.2) ]. additional important information regarding the use of viramune xr for the treatment of hiv-1 infection: - based on serious and life-threatening hepatotoxicity observed in controlled and uncontrolled trials, nevirapine should not be initiated in adult females with cd4+ cell counts greater than 250 cells/mm3 or in adult males with cd4+ cell counts greater than 400 cells/mm3 unless the benefit outweighs the risk [see boxed warning and warnings and precautions (5.1) ]. - the 14-day lead-in period with immediate-release viramune dosing must be strictly followed; it has been demonstrated to reduce the frequency of rash [see dosage and administration (2.5) and warnings and precautions (5.2) ]. - if rash persists beyond the 14-day lead-in period with immediate-release viramune, do not begin dosing with

United States - English - NLM (National Library of Medicine)

carilion materials management - disopyramide phosphate (unii: n6bom1935w) (disopyramide - unii:gfo928u8mq) - disopyramide 150 mg - norpace and norpace cr are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. because of the proarrhythmic effects of norpace and norpace cr, their use with lesser arrhythmias is generally not recommended. treatment of patients with asymptomatic ventricular premature contractions should be avoided. initiation of norpace or norpace cr treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. norpace cr should not be used initially if rapid establishment of disopyramide plasma levels is desired. antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. norpace and norpace cr are contraindicated in the presence of cardiogenic shock, preexisting second- or third-degree av block (if no pacemaker is present), congenital q-t prolongation, or known hypersensitivity to the drug.

United States - English - NLM (National Library of Medicine)

carilion materials management - disopyramide phosphate (unii: n6bom1935w) (disopyramide - unii:gfo928u8mq) - disopyramide 100 mg - norpace and norpace cr are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. because of the proarrhythmic effects of norpace and norpace cr, their use with lesser arrhythmias is generally not recommended. treatment of patients with asymptomatic ventricular premature contractions should be avoided. initiation of norpace or norpace cr treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. norpace cr should not be used initially if rapid establishment of disopyramide plasma levels is desired. antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. norpace and norpace cr are contraindicated in the presence of cardiogenic shock, preexisting second- or third-degree av block (if no pacemaker is present), congenital q-t prolongation, or known hypersensitivity to the drug.

United States - English - NLM (National Library of Medicine)

carlsbad technology, inc. - nevirapine (unii: 99dk7fvk1h) (nevirapine - unii:99dk7fvk1h) - nevirapine 200 mg - nevirapine is indicated for combination antiretroviral treatment of hiv-1 infection in adults and in pediatrics patients 15 days and older [ see clinical studies ( 14.1), ( 14.2) ]. additional important information regarding the use of nevirapine for the treatment of hiv-1 infection: - based on serious and life-threatening hepatotoxicity observed in controlled and uncontrolled trials, nevirapine should not be initiated in adult females with cd4 + cell counts greater than 250 cells/mm3 or in adult males with cd4 + cell counts greater than 400 cells/mm 3 unless the benefit outweighs the risk [ see boxed warning and warnings and precautions ( 5.1) ]. - the 14-day lead-in period with nevirapine 200 mg daily dosing must be strictly followed; it has been demonstrated to reduce the frequency of rash [ see dosage and administration (

Australia - English - Department of Health (Therapeutic Goods Administration)

proqualix pty ltd - in administration - disopyramide phosphate, quantity: 193.2 mg - tablet - excipient ingredients: hard paraffin; polyvinyl acetate; magnesium stearate; hypromellose; macrogol 6000; titanium dioxide - indications for: new zealand and thailand,norpace is indicated for the treatment and prevention of recurrence of the following cardiac arrhythmias when they occur singly or in combination. premature atrial contractions. paroxysmal supraventricular tachycardia, including that associated with the wolf-parkinson- white syndrome. maintenance of normal sinus rythm following electroconversion of atrial flutter or atrial fibrillation. premature ventricular contractions-whether unifocal, multi-focal or coupled. ventricular tachycardia. norpace is equally effective whether or not the patient has had a myocardial infarction and also whether or not the patient is receiving digitalis. norpace should only be administered to patients with congestive heart failure when the condition is adequately controlled. norpace should generally be prescribed only after appropiate electrocardiopgraphic assessment. indications for: singapore & hong kong, ventricular arrhythmia as well as ventricular extrasystoles and ventricular tachycar

Ireland - English - HPRA (Health Products Regulatory Authority)

g.d. searle & company limited - disopyramide - capsule - 100 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

g.d. searle & company limited - disopyramide - capsule - 150 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

g.d. searle & company limited - disopyramide phosphate - 5 millilitre